Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Prostatic Neoplasms 25Lymphoma, Large B-Cell, Diffuse 24Burkitt Lymphoma 19Lymphoma, Follicular 14Lymphoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Neoplasms 8Lymphoma, Non-Hodgkin 8Lymphoma, B-Cell 6Recurrence 5Prostatic Neoplasms, Castration-Resistant 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Biphenotypic, Acute 4Ovarian Neoplasms 3Lymphoproliferative Disorders 3Lymphoma, T-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Prostate Cancer Metastatic 2Plasmablastic Lymphoma 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer 2Melanoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Enteropathy-Associated T-Cell Lymphoma 2

Interventions

pembrolizumab 6avelumab 6Nivolumab 5Specimen Handling 4Magnetic Resonance Spectroscopy 3Biopsy 3prednylidene 2lutetium Lu 177 dotatate 2deltacortene 2Prednisone 2Ipilimumab 2CTLA-4 Antigen 2talimogene laherparepvec 1lenvatinib 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1cemiplimab 1aldesleukin 1Tacrolimus 1Sirolimus 1Saline Solution 1Radiotherapy 1Radiosurgery 1MAPRE1 protein, human 1Lutetium-177 1Laparoscopy 1Exercise Test 1Cyclophosphamide 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Merkel Cell × Prednisone × 90 days × Clear all
NCT05896839 2026-05-13

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
16 enrolled
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT03816332 2026-04-30

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
12 enrolled 13 charts
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡